Vera rises on early kidney function data in FDA review
BUZZ-Vera rises on early kidney function data in FDA review ** Shares of Vera Therapeutics VERA.O rise 10.4% to $31.89
** U.S. FDA published its review documents supporting the accelerated approval of Vera's drug, Trutakna, for patients with immunoglobulin A nephropathy
** The documents included an early look at estimated glomerular filtration rate (eGFR), a measure of kidney function, ahead of a late-stage data readout expected in Q3 2026
** Jefferies says "We view this as reassuring and supportive of the view that atacicept's (Trutakna) long-term eGFR profile could ultimately track closely to Otsuka's 4578.T sibeprenlimab"
** FDA said preliminary eGFR data appeared "promising," but the available evidence was insufficient to support traditional approval because data beyond Week 36 were limited
** FDA added that data from ongoing study is adequately powered and clinical benefit is "highly likely" to be verified
** "We remain bullish on VERA given the value we expect the company to create as it launches Trutakna into the large and growing IgAN market," Guggenheim says
** Including session moves, stock down 15.2% YTD
(Reporting by Siddhi Mahatole)
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug